RankAlpha logo
Back to Rankings

INSM

InsmedB
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
View Chart
Current thesis
BRINSUPRI sustains its rapid launch trajectory, ARIKAYCE wins broader U.S. approval, and TPIP development advances, supporting a materially larger respiratory franchise.
Posture
Constructive
Lead driver
Sentiment
What changed
Next scheduled catalyst: earnings 2026-10-29 · BMO.
What can break
ARIKAYCE Priority Review does not guarantee approval or a broader label; its existing U.S. indication remains narrower. Insmed release
Momentum
9
Value
41
Sentiment
82
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $119.00 · Bull $155.00 · Bear $75.00Analysis 2026-10-02; returns require an exact persisted reference.
Earnings
2026-10-29 · BMO
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-02 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-10-23

Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions

Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $196.14
Why
Momentum9 · Δ7d -8.7
Value41 · Δ7d -0.1
Sentiment82 · Δ7d +4.9
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.

Confirming evidence

  • • Next scheduled catalyst: earnings 2026-10-29 · BMO.
  • • Sentiment remains the lead driver in the composite, 7D delta +4.9.

Contradictions & invalidation

  • • ARIKAYCE Priority Review does not guarantee approval or a broader label; its existing U.S. indication remains narrower. Insmed release
  • • BRINSUPRI launch results depend on patient uptake, reimbursement, adherence and adequate manufacturing supply despite Japanese approval. Insmed Japan release
  • • BRINSUPRI uptake or reimbursement could disappoint against raised guidance; ARIKAYCE's review could be delayed or unsuccessful; and TPIP Phase 3 expansion increases spending before efficacy is established.

Catalyst clock

2026-10-29 · BMO

BRINSUPRI launch and guidance delivery

Lead driver: Sentiment · See AI snapshot
Momentum
9
8% active weight
Current posture
7d trendFlat
Δ7d
-8.7
Δ21d
-39.1
Value
41
47% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.4
Sentiment
82
45% active weight
Current posture
7d trendFlat
Δ7d
+4.9
Δ21d
+11.4
Why this grade

Composite grade B. Momentum 9.1 / Value 40.6 / Sentiment 82.3

Scenario snapshot

Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-02. Scenario method

B+
Bull case
25%
Probability
Target price
$155.00
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
Most likely
B
Base case
50%
Probability
Target price
$119.00
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$75.00
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$20.39B
Beta
1.11
Shares Out
218.38M
P/E (TTM) · Derived
-14.6
P/S (TTM)
83.59
P/FCF (TTM) · Derived
-23.86
Rev YoY
+296.1%
EPS YoY
-96.4%
Gross Margin
+82.8%
Op Margin
-71.4%
Net Debt
-$674.06M
Current Ratio
3.72
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data